Arch Therapeutics Launches Coverage and Reimbursement PilotCritical Next Step in Commercialization Plan Commences

Arch Therapeutics Launches Coverage and Reimbursement PilotCritical Next Step in Commercialization Plan Commences
FRAMINGHAM, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) — Arch Therapeutics (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced the launch of its coverage and reimbursement pilot (the “Pilot”) in collaboration with The Reimbursement Group (“TRG”) for the Company’s AC5® Advanced Wound System.

Read the source article at biospace.com
2021-10-04 04:00:00